Kent Edwards
Urology · Lenoir, NCNPI 1730530502
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Boston Scientific at 29.3% of the total. Reporting peaked in 2022 at $654 and has fallen 51.3% since, to $318 in 2025. That places this record below the midpoint for urology clinicians in NC, where the typical reported total is $2,562.
Across 77 payments — averaging $33.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$745
- Medtronic$628
- Astellas Pharma US Inc$172
- Endo Pharmaceuticals Inc.$164
- Laborie Medical Technologies Corp.$124
- Coloplast$119
- plus $591 from 11 others
What the payments were for
- Food & beverage$2,44396%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $745 |
| Medtronic(2 entities) | 31 | $628 |
| Astellas Pharma US Inc | 4 | $172 |
| Endo Pharmaceuticals Inc. | 4 | $164 |
| Laborie Medical Technologies Corp. | 3 | $124 |
| Coloplast | 6 | $119 |
| Calyxo, Inc. | 1 | $117 |
| Olympus America Inc. | 2 | $114 |
| Teleflex LLC | 2 | $109 |
| Axonics, Inc. | 1 | $58 |
| Mission Pharmacal Company | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $34 |
| Ambu Inc. | 1 | $31 |
| KARL Storz Endoscopy-america | 1 | $26 |
| Tolmar, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$216
- LithoVue$119
- CVAC Aspiration System$117
- XIAFLEX$114
How this compares
$2,543 in reported general payments places this provider in the 45th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 311 | $182,750 |
| GemtesaVibegron | 208 | $139,712 |
| Methenamine Hippurate | 325 | $17,005 |
| Tamsulosin Hcl | 821 | $8,618 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 212 | $6,903 |
| Solifenacin Succinate | 199 | $5,769 |
| Finasteride | 342 | $3,831 |
| Trospium Chloride ErTrospium Chloride | 19 | $3,319 |
| Potassium Citrate ErPotassium Citrate | 34 | $2,946 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 66 | $2,036 |
| Oxybutynin Chloride ErOxybutynin Chloride | 205 | $1,984 |
| Cefdinir | 90 | $1,317 |
| Trospium Chloride | 25 | $1,266 |
| Dutasteride | 43 | $1,032 |
| Ciprofloxacin Hcl | 76 | $762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $172 | $182,750311 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $21 | $139,712208 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 434 urology providers in North Carolina.
Other urology in Lenoir
- Robert LippittSmithfield$11.4M
- Michael KennellyCharlotte$1.3M
- John KasparRaleigh$1.1M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Scott MacdiarmidGreensboro$774K
- Glenn PremingerDurham$736K
- Michael LipkinDurham$293K
- Culley CarsonChapel Hill$275K
- Aaron LentzRaleigh$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.